- Trials with a EudraCT protocol (43)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
43 result(s) found for: Bcl6.
Displaying page 1 of 3.
EudraCT Number: 2019-002291-13 | Sponsor Protocol Number: KTE-C19-112 | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:Kite Pharma, Inc | |||||||||||||
Full Title: A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12) | |||||||||||||
Medical condition: Adult subjects with high-risk large B-cell lymphoma, including either high-grade B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 translocations (double-hit or triple-hit lymphomas) or Internat... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003908-14 | Sponsor Protocol Number: M-2020-371 | Start Date*: 2021-07-07 | ||||||||||||||||
Sponsor Name:Miltenyi Biomedicine GmbH | ||||||||||||||||||
Full Title: A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diff... | ||||||||||||||||||
Medical condition: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Ongoing) ES (Ongoing) HU (Ongoing) CZ (Trial now transitioned) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003631-12 | Sponsor Protocol Number: HOVON152 | Start Date*: 2018-07-26 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 r... | |||||||||||||
Medical condition: Diffuse large B cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000933-37 | Sponsor Protocol Number: CRT113890 | Start Date*: 2012-09-18 |
Sponsor Name:National and Kapodostrian University of Athens | ||
Full Title: Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previ... | ||
Medical condition: Relapsed or refractory diffuse large B cell lymphoma (DLBCL). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005225-81 | Sponsor Protocol Number: VALYM | Start Date*: 2021-04-28 | ||||||||||||||||
Sponsor Name:LYSARC | ||||||||||||||||||
Full Title: A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
Medical condition: RELAPSE/REFRACTORY B-CELL LYMPHOMA | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) BE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005861-41 | Sponsor Protocol Number: MK-2140-007 | Start Date*: 2022-06-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL | |||||||||||||
Medical condition: Diffuse Large B-cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000106-38 | Sponsor Protocol Number: JCAR017-BCM-001 | Start Date*: 2018-06-14 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCEND WORLD) | ||||||||||||||||||
Medical condition: Aggressive B-cell Non Hodgkin Lymphoma (B-NHL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) FI (Completed) ES (Restarted) DE (Completed) AT (Completed) NL (Ongoing) GB (Temporarily Halted) IT (Restarted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004288-11 | Sponsor Protocol Number: ADCT-402-201 | Start Date*: 2018-08-10 |
Sponsor Name:ADC Therapeutics SA | ||
Full Title: A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | ||
Medical condition: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2015-003429-32 | Sponsor Protocol Number: ImbruVeRCHOP-Trial | Start Date*: 2017-02-09 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2” | ||
Medical condition: untreated CD20-positive DLBCL-like aggressive Non-Hodgkin’s lymphoma, 61-80 years of age with unfavorable risk profile (IPI ≥ 2) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002654-39 | Sponsor Protocol Number: HO130 | Start Date*: 2015-02-25 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U | ||||||||||||||||||
Medical condition: MYC positive diffuse large B cell lymphoma and Burkitt lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001147-24 | Sponsor Protocol Number: ONC-2021-001 | Start Date*: 2023-04-12 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: Use of LOncastuximab Tesirine in patients with RElapsed/Refractory Diffuse Large B-Cell LYmphoma (DLBCL) or High Grade B-Cell Lymphoma (HGBCL) who have progressive disease after CAR T-cell treatmen... | |||||||||||||
Medical condition: Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-cell therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000842-36 | Sponsor Protocol Number: Version128May2019 | Start Date*: 2020-04-07 | |||||||||||
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||
Full Title: A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma in patients with co-morbidities who cannot tolerate full dose R-CHOP. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003397-32 | Sponsor Protocol Number: MK2140-004 | Start Date*: 2022-01-14 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) PL (Trial now transitioned) NO (Trial now transitioned) EE (Ongoing) CZ (Ongoing) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002023-21 | Sponsor Protocol Number: GO39942 | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB ... | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) CZ (Ongoing) PT (Completed) BE (Ongoing) AT (Ongoing) FR (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002990-84 | Sponsor Protocol Number: MOR208C310 | Start Date*: 2021-03-01 | ||||||||||||||||
Sponsor Name:MorphoSys AG | ||||||||||||||||||
Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untre... | ||||||||||||||||||
Medical condition: Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) IE (Ongoing) DE (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) HU (Ongoing) AT (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003016-27 | Sponsor Protocol Number: GCT3013-05 | Start Date*: 2021-04-06 | |||||||||||
Sponsor Name:Genmab A/S | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma | |||||||||||||
Medical condition: B-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004977-38 | Sponsor Protocol Number: VERLEN | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:LYSARC | |||||||||||||
Full Title: Phase II, Open-Label Study evaluating efficacy of Tafasitamab and Lenalinomide associated to Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older | |||||||||||||
Medical condition: Frontline DLBCL | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004336-30 | Sponsor Protocol Number: CYTB323A12101 | Start Date*: 2020-04-07 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL. | ||
Medical condition: ALL, CLL/SLL and DLBCL and High-Risk LBCL. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016026-13 | Sponsor Protocol Number: O-ESHAP-LH-2009 | Start Date*: 2010-05-18 | |||||||||||
Sponsor Name:FUNDACION GELTAMO | |||||||||||||
Full Title: Estudio de fase II de uso de anticuerpo monoclonal anti-CD20 (ofatumumab) más ESHAP seguido de trasplante autólogo de progenitores hemopoyéticos para el tratamiento de linfoma de Hodgkin clásico en... | |||||||||||||
Medical condition: EL PRESENTE ESTUDIO PROPONE TRATAR PACIENTES CON LINFOMA DE HODGKIN CLASICO REFRACTARIO, EN RESPUESTA PARCIAL O RECAIDA CON QUIMIOTERAPIA SEGUN DOSIS ESTANDAR DE ESHAP EN COMBINACION CON OFATUMUMAB... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004522-29 | Sponsor Protocol Number: UCL/17/0920 | Start Date*: 2019-10-28 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Phase Ib/II trial of Histone Deacetylase Inhibitor CXD101 in combination with Programmed Cell Death Protein-1 Inhibitor Pembrolizumab for relapsed or refractory Diffuse Large B-cell Lymphoma | ||||||||||||||||||
Medical condition: Relapsed and refractory Diffuse Large B-cell Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.